Insider Purchases: Inside the Buy
Tag: healthcare stocks
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.
🏥 Elevance Health (NYSE: ELV): The CEO Bought Again. We're Still Buying the Story.
Exactly one year after publishing our original bullish thesis on Elevance Health, we're revisiting the story. Shares are up nearly 26%, yet the core investment case remains surprisingly intact. CEO Gail Boudreaux just bought another $1 million worth of stock, institutions continue to hold over 93% of shares, and valuation still looks attractive.
🩺 Abbott Laboratories (ABT) Stock Analysis: Can a Dividend King Turn Exact Sciences Into Its Next Growth Engine?
Abbott Laboratories may not be flashy, but the healthcare giant combines insider buying, a growing oncology diagnostics platform, the dominant FreeStyle Libre franchise, and more than a century of dividend payments. With shares trading near 16x forward earnings, investors may be looking at a classic Growth at a Reasonable Price opportunity.
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse
Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.
🐾 Zoetis (ZTS): A Premium Veterinary Titan Sitting in the Doghouse
Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?
🩺 GE HealthCare (GEHC): Insider Buying, AI Growth & a $21B Backlog Opportunity
GE HealthCare (GEHC) is quietly shaping up as a high-visibility MedTech play, combining insider buying, a $21.8B backlog, and AI-driven diagnostics. With valuation still reasonable and institutional ownership near record levels, this could be a compelling long-term compounder—if you’re patient on entry.
PODD Stock Analysis 2026: Is Insulet the Ultimate Growth Play or a Valuation Trap?
Insulet (PODD) just delivered 31% revenue growth and insiders are buying — yet the stock trades at 70x earnings. Is this premium medtech compounder a long-term winner or priced for perfection? Here’s the FUNanc1al breakdown.
CEO Purchases Abbott Shares, But the Stock Carries Risks
Abbott’s CEO just stepped in with a $2M insider buy — analysts are bullish, shorts are scarce, and institutions remain locked in. Tempting? Yes. Risk-free? Not quite.
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.